Journal Mobile Options
Table of Contents
Vol. 83, No. 1-2, 2011
Issue release date: November 2010
Digestion 2011;83:32–40

Association of Serum Adipocytokines with Hepatic Steatosis and Fibrosis in Patients with Chronic Hepatitis C

Baranova A. · Jarrar M.H. · Stepanova M. · Johnson A. · Rafiq N. · Gramlich T. · Chandhoke V. · Younossi Z.M.
aTranslational Research Institute, Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Va., bMolecular and Microbiology Department and Center for the Study of Genomics in Liver Diseases, George Mason University, Fairfax, Va., cCenter for Liver Diseases, Inova Fairfax Hospital, Falls Church, Va., and dAmeriPath, Cleveland, Ohio, USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: The pathogenic mechanisms of hepatic steatosis in hepatitis C (HCV) remain unclear. Aim: To assess the potential role of cytokines and adipokines in HCV-related steatosis and fibrosis. Methods: We profiled several adipokines, cytokines, and related soluble molecules in 99 HCV patients and analyzed their potential associations with hepatic steatosis and fibrosis. Results: Serum leptin and IL-1RA were significantly higher in HCV genotype 1 as compared to genotype 3. On the other hand, serum resistin, IL-8, IL-1B and sIL-6R, were significantly higher in HCV genotype 3. No differences were observed for adiponectin, visfatin, IL-6 and TNF-α. Regardless of HCV genotype, steatosis could be predicted by a combination of IL-8, IL-6, and sIL-6R/IL-6. When analysis was repeated for each of the genotypes, the reliability of models improved. Regardless of HCV genotype, moderate to severe fibrosis (Metavir score >F2), was predicted by IL-8 and resistin levels. Conclusions: Analysis of adipocytokines associated with steatosis supports the hypothesis that steatogenic pathways differ in HCV genotype 3 from those infected with non-genotype 3 infections.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Björnsson E, Angulo P: Hepatitis C and steatosis. Arch Med Res 2007;38:621–627.
  2. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, et al; HCV Meta-Analysis (on) Individual Patients’ Data Study Group: Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006;130:1636–1642.
  3. Tanaka A, Uegaki S, Kurihara H, Aida K, Mikami M, Nagashima I, Shiga J, Takikawa H: Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. World J Gastroenterol 2007;13:5180–5187.
  4. Younossi ZM, McCullough AJ: Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. Liver Int 2009;29:3–12.
  5. Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallée M, et al: The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004;40:484–490.
  6. Dev A, Patel K, McHutchison JG: Hepatitis C and steatosis. Clin Liver Dis 2004;8:881–892.
  7. Kim KH, Hong SP, Kim K, Park MJ, Kim KJ, Cheong J: HCV core protein induces hepatic lipid accumulation by activating SREBP1 and PPARγ. Biochem Biophys Res Commun 2007;355:883–888.
  8. Jackel-Cram C, Babiuk LA, Liu Q: Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. J Hepatol 2007;46:999–1008.
  9. Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S: Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with non-alcoholic fatty liver disease. Gastroenterology 2008;134:424–431.
  10. Yamaguchi A, Tazuma S, Nishioka T, Ohishi W, Hyogo H, Nomura S, Chayama K: Hepatitis C virus core protein modulates fatty acid metabolism and thereby causes lipid accumulation in the liver. Dig Dis Sci 2005;50:1361–1371.
  11. Hézode C, Roudot-Thoraval F, Zafrani ES, Dhumeaux D, Pawlotsky JM: Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections. J Viral Hepat 2004;11:455–458.
  12. Muzzi A, Leandro G, Rubbia-Brandt L, James R, Keiser O, Malinverni R, et al: Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol 2005;42:41–46.
  13. Castera L, Chouteau P, Hezode C, Zafrani ES, Dhumeaux D, Pawlotsky JM: Hepatitis C virus-induced hepatocellular steatosis. Am J Gastroenterol 2005;100:711–715.
  14. Mengshol JA, Golden-Mason L, Rosen HR: Mechanisms of disease: HCV-induced liver injury. Nat Clin Pract Gastroenterol Hepatol 2007;4:622–634.
  15. Seronello S, Sheikh MY, Choi J: Redox regulation of hepatitis C in non-alcoholic and alcoholic liver. Free Radic Biol Med 2007;43:869–882.
  16. Lonardo A, Loria P, Adinolfi LE, Carulli N, Ruggiero G: Hepatitis C and steatosis: a reappraisal. J Viral Hepat 2006;13:73–80.
  17. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL: Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002;36:729–736.
  18. Cua IH, Hui JM, Bandara P, Kench JG, Farrell GC, McCaughan GW, George J: Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology 2007;46:66–73.
  19. Durante-Mangoni E, Zampino R, Marrone A, Tripodi MF, Rinaldi L, Restivo L, et al: Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-α in chronic hepatitis C patients. Aliment Pharmacol Ther 2006;24:1349–1357.
  20. Tsochatzis E, Papatheodoridis GV, Archimandritis AJ: The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol 2006;101:2629–2640.
  21. Bedossa P, Poynard T: An algorithm for the grading of activity in chronic hepatitis C. The Metavir Cooperative Study Group. Hepatology 1996;24:289–293.
  22. Younossi ZM, Gramlich T, Liu YC, Matteoni C, Petrelli M, Goldblum J, Rybicki L, McCullough AJ: Non-alcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol 1998;11:560–565.
  23. Kohavi R: A study of cross-validation and bootstrap for accuracy estimation and model selection. Proceedings of the Fourteenth International Joint Conference on Artificial Intelligence, Montreal 1995, vol 2, pp 1137–1143.
  24. Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, Fang Y, Elariny H, Goodman Z, Chandhoke V, Younossi ZM: Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008;27:412–421.
  25. Manning PJ, Sutherland WH, McGrath MM, de Jong SA, Walker RJ, Williams MJ: Postprandial cytokine concentrations and meal composition in obese and lean women. Obesity (Silver Spring) 2008;16:2046–2052.
  26. Hung CH, Lee CM, Chen CH, Hu TH, Jiang SR, Wang JH, Lu SN, Wang PW: Association of inflammatory and anti-inflammatory cytokines with insulin resistance in chronic hepatitis C. Liver Int 2009;29:1086–1093.
  27. Tacke F, Wüstefeld T, Horn R, et al: High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J Hepatol 2005;42:666–673.
  28. Kaser S, Moschen A, Kaser A, et al: Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis. J Intern Med 2005;258:274–280.
  29. Akeno N, Blackard JT, Tomer Y: HCV E2 protein binds directly to thyroid cells and induces IL-8 production: a new mechanism for HCV-induced thyroid autoimmunity. J Autoimmun 2008;31:339–344.
  30. Scheller J, Ohnesorge N, Rose-John S: Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol 2006;63:321–329.
  31. El-Assal O, Hong F, Kim WH, Radaeva S, Gao B: IL-6-deficient mice are susceptible to ethanol-induced hepatic steatosis: IL-6 protects against ethanol-induced oxidative stress and mitochondrial permeability transition in the liver. Cell Mol Immunol 2004;1:205–211.
  32. Hong F, Radaeva S, Pan HN, Tian Z, Veech R, Gao B: Interleukin-6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease. Hepatology 2004;40:933–934.
  33. Lee SS, Park SH, Kim HJ, Kim SY, Kim MY, Kim DY, Suh DJ, Kim KM, Bae MH, Lee JY, Lee SG, Yu ES: Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol 2010;52:579–585.
  34. Younossi ZM, Baranova A, Afendy A, Collantes R, Stepanova M, Manyam G, et al: Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferon-alfa and ribavirin. Hepatology 2009;49:763–774.
  35. Huang C, Chen H, Cassidy W, Howell CD: Peripheral blood gene expression profile associated with sustained virologic response after peginterferon plus ribavirin therapy for chronic hepatitis-C genotype 1. J Natl Med Assoc 2008;100:1425–1433.
  36. Bertolani C, Sancho-Bru P, Failli P, Bataller R, Aleffi S, DeFranco R, et al: Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am J Pathol 2006;169:2042–2053.
  37. Tsochatzis E, Papatheodoridis GV, Hadziyannis E, Georgiou A, Kafiri G, Tiniakos DG, Manesis EK, Archimandritis AJ: Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Scand J Gastroenterol 2008;43:1128–1136.
  38. Mahmood S, Sho M, Yasuhara Y, Kawanaka M, Niiyama G, Togawa K, et al: Clinical significance of intrahepatic interleukin-8 in chronic hepatitis C patients. Hepatol Res 2002;24:413–419.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50